Skip to content
About
About Us
Team & Board
Generic Medicines
Our Members
Advocacy & Policy
Overview
Federal Advocacy
State Advocacy
Tariff & Trade
Biosimilars
GDUFA/BsUFA User Fees
IP & Patent Reform
Inflation Reduction Act
Medicaid Generics Penalty
Resources
Resource Center
Generic & Biosimilar
Medicines Savings Report
Advocacy Priorities
Biosimilars
Events
All Events
GRx+Biosims 2026
Access! 2027
About
About Us
Team & Board
Generic Medicines
Our Members
Advocacy & Policy
Overview
Federal Advocacy
State Advocacy
Tariff & Trade
Biosimilars
GDUFA/BsUFA User Fees
IP & Patent Reform
Inflation Reduction Act
Medicaid Generics Penalty
Resources
Resource Center
Generic & Biosimilar
Medicines Savings Report
Advocacy Priorities
Biosimilars
Events
All Events
GRx+Biosims 2026
Access! 2027
JOIN
SEARCH
Home
Blog
Biosimilars Council Press Releases
Blog
Blog
August 24, 2018
AAM
What They Are Saying – Blocking Access to Samples
Blog
August 24, 2018
AAM
Group Letter in Support of CREATES Act
Blog
August 24, 2018
AAM
Restricted Access Drug Programs Impeding Patient Access to Generic Drugs: Myths and Facts Regarding Maine LD 1280
Blog
August 8, 2018
AAM
Using Safety Programs to Protect Profits, Not Patients
Blog
August 7, 2018
AAM
Pharmaceutical Patent Abuse: To Infinity and Beyond!
Blog
August 1, 2018
AAM
Patients Can See Their Savings
Blog
July 26, 2018
AAM
Keon is Playing Hip Hop in NYC
Blog
July 23, 2018
AAM
Ariel is a Cancer Thriver
Blog
July 19, 2018
AAM
The Medicaid Generics Penalty: Understanding Market Dynamics (Part 2)
Blog
July 10, 2018
AAM
Cotton-McCaskill PACED Act Would Help Patients Gain Access to More Affordable Generics
Blog
June 20, 2018
AAM
Pass the CREATES Act to End Manipulative Practices That Cost Our Patients Billions
Blog
June 8, 2018
AAM
House Subcommittee Examines the Drug Supply Chain
Load More
Resources
2025 Savings Report
2025 Advocacy Priorities
2025 First Generics White Paper
Drug Shortages White Paper
Biosimilars Patient Resource Center
Biosimilar Research & Studies
Blog
Founders Blogs
Amicus Briefs
Patient Stories
About the Association
Generic Quality
About AAM
Our Team
Our Members
Generic Medicines
Biosimilars Council
Meet Our Board
Community Commitment
Careers
Contact Us
Advocacy & Policy
Federal Advocacy
Biosimilars
GDUFA/BsUFA User Fees
Inflation Reduction Act
Intellectual Property & Patent Reform
Medicaid Generics Penalty
State Advocacy
Tariffs & Trade
Events
Access! 2026
GRx+Biosims 2026
Press Releases
JOIN
About
About Us
Team & Board
Generic Medicines
Our Members
Advocacy & Policy
Overview
Federal Advocacy
State Advocacy
Tariff & Trade
Biosimilars
GDUFA/BsUFA User Fees
IP & Patent Reform
Inflation Reduction Act
Medicaid Generics Penalty
Resources
Resource Center
Generic & Biosimilar
Medicines Savings Report
Advocacy Priorities
Biosimilars
Events
All Events
GRx+Biosims 2026
Access! 2027
JOIN
SEARCH
